4.7 Article

Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Immunology

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Paul E. Sax et al.

Summary: The study findings suggest that B/F/TAF can replace DTG+ F/TAF or F/TDF for treating HIV-1 without compromising safety or efficacy, and is suitable for patients with NRTI resistance.

CLINICAL INFECTIOUS DISEASES (2021)

Article Immunology

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation

Ignacio Perez-Valero et al.

Summary: Switching to E/C/F/TAF from a tenofovir disoproxil fumarate-based or ABC-based regimen maintained high rates of virologic suppression in adults with M184V/I resistance mutations, with good tolerability throughout 48 weeks of therapy.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2021)

Article Infectious Diseases

Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

David Rial-Crestelo et al.

Summary: In the ART-PRO pilot trial, treatment with dolutegravir plus lamivudine maintained virological suppression at 96 weeks without any virological failures. Baseline proviral DNA sequencing revealed lamivudine resistance mutations in participants.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Article Infectious Diseases

Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial)

Constance Delaugerre et al.

Summary: The study found that using Ultra-deep sequencing (UDS) to analyze M184V/I variants in HIV carriers detected both M184V and M184I mutations, with M184I mutation being associated with defective virus. The antiviral efficacy of the lamivudine-based dual therapy regimen is mainly due to the residual lamivudine activity, as evidenced by the research.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Article Virology

Routine drug resistance testing in HIV-1 proviral DNA, using an automated next-generation sequencing assay

Enagnon Kazali Alidjinou et al.

JOURNAL OF CLINICAL VIROLOGY (2019)

Article Infectious Diseases

Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART

A. Nouchi et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)

Review Medicine, General & Internal

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2018 Recommendations of the International Antiviral Society-USA Panel

Michael S. Saag et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)

Article Infectious Diseases

RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients

E. K. Alidjinou et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)

Review Virology

Deep sequencing for HIV-1 clinical management

Maria Casadella et al.

VIRUS RESEARCH (2017)

Article Biochemical Research Methods

Quality control and preprocessing of metagenomic datasets

Robert Schmieder et al.

BIOINFORMATICS (2011)

Article Biochemical Research Methods

FLASH: fast length adjustment of short reads to improve genome assemblies

Tanja Magoc et al.

BIOINFORMATICS (2011)

Review Pharmacology & Pharmacy

Clinical management of HIV-1 resistance

Roger Paredes et al.

ANTIVIRAL RESEARCH (2010)